Yahoo Web Search

Search results

1. • 

     Regeneron stock defended at RBC after DOJ suit (NASDAQ:REGN)

     Seeking Alpha· 1 week ago

     Regeneron (REGN) stock remains a buying opportunity, RBC Capital Markets said, after the Department...

2. • Q1 2024 Earnings Estimate for Sanofi (NASDAQ:SNY) Issued By Leerink Partnrs

     ETF DAILY NEWS· 1 day ago

     Sanofi (NASDAQ:SNY – Free Report) – Equities researchers at Leerink Partnrs cut their Q1 2024 earnings per share estimates for shares of Sanofi in a report issued on Tuesday, April 16th. Leerink ...

3. • 

     Why won’t health insurance companies pay for new drugs? - The Boston Globe

     The Boston Globe· 1 week ago

     This is just the latest example of the CMS putting the brakes on FDA-approved drugs. The federal...

4. • Drugmakers OD On Insane Prices, Incessant Commercials

     The Post-Journal· 2 weeks ago

     Lastly, the companies argue that critics of high prices should instead be praising the industry for all the research it carries out to make the drugs available in the first place–failing to ...

5. • 

     Connect Biopharma uncouples from Pfizer by scrapping long-standing eczema pact

     FierceBiotech· 3 days ago

     Chinese-American biotech Connect licensed the oral, peripherally acting H3R antagonist, dubbed...

6. • Brokerages Set Sanofi (NASDAQ:SNY) Price Target at $55.00

     ETF DAILY NEWS· 24 hours ago

     One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and two have given a buy recommendation to the company ...

7. • Clarius Group LLC Cuts Stock Position in Sanofi (NASDAQ:SNY)

     ETF DAILY NEWS· 6 days ago

     The firm owned 8,641 shares of the company’s stock after selling 742 shares during the quarter. Clarius Group LLC’s holdings in Sanofi were worth $430,000 at the end of the ...

8. • 4,040 Shares in Sanofi (NASDAQ:SNY) Purchased by Prime Capital Investment Advisors LLC

     ETF DAILY NEWS· 5 days ago

     Prime Capital Investment Advisors LLC purchased a new position in Sanofi (NASDAQ:SNY – Free Report) in the 4th quarter, according to the company in its most recent filing ...